Novel vaginal controlled-delivery systems incorporating coprecipitates of Nonoxynol-9

Pharmaceutical Development and Technology

Volumn 4, Issue 3, 1999, Pages 421-430

  Digenis, G A ^a   Nosek, D ^a   Mohammadi, F ^a   Darwazeh, N B ^a   Anwar, H S ^a   Zavos, P M ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bilayer tablet; Drug delivery; Formulations; Human semen; Human seminal plasma; Intravaginal; Iodine; Multicompartment hard gelatin capsule; Nonoxynol 9; PVP; Rabbits; Release rates; Sustained release

Indexed keywords

GELATIN; NONOXINOL 9; POVIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILAYER MEMBRANE; CAPSULE FILLING; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; FEMALE; NONHUMAN; PELLET EXTRUSION; PRIORITY JOURNAL; RABBIT; SEMINAL PLASMA; SUSTAINED RELEASE PREPARATION; TABLET;

ADMINISTRATION, INTRAVAGINAL; ANIMALS; CAPSULES; DELAYED-ACTION PREPARATIONS; FEMALE; GELATIN; HUMANS; HYDROGEN-ION CONCENTRATION; IODINE; LIPID BILAYERS; NONOXYNOL; PHARMACEUTIC AIDS; POVIDONE; RABBITS; SEMEN; SPERMATOCIDAL AGENTS; TABLETS;

EID: 0032782621     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-100101378     Document Type: Article

References (20)

1. B. A. Walter, A. A. Hawi, P. M. Zavos, and G. A. Digenis, Solubilization and in vitro spermicidal assessment of nonoxynol-9 and selected fractions using rabbit spermatozoa, Pharm. Res., 8, 403-408 (1991).
2. B. A. Walter and G. A. Digenis, High-performance liquid Chromatographic (HPLC) analysis of oligomeric components of the spermicide nonoxynol-9, Pharm. Res., 8, 409-411 (1991).
3. M. A. Liebert, Final report on the safety assessment of the nonoxynols -2, -4, -8, -9, -10, -12, -14, -15. -30, -40 and -50, J. Am. Coll. Toxicol., 2, 35 (1983).
4. P. M. Zavos, J. R. Correa, D. Nosek, F. Mohammadi, and G. A. Digenis, Comparative spermicidal performance of iodinated and non-iodinated contraceptive formulations of nonoxynol-9 co-precipitated with polyvinylpyrrolidone, Contraception, 54, 39-41 (1996).
5. P. M. Zavos, J. R. Correa, D. Nosek, F. Mohammadi, and G. A. Digenis, Assessment of new formulations of nonoxynol-9 coprecipitated with polyvinylpyrrolidone and iodine as possible vaginal contraceptives, Fertil. Steril., 5, 729-733 (1996).
6. 14C] nonoxynol-9 after intravenous or vaginal administration to female Sprague-Dawley rats, Toxicol. Appl. Pharmacol., 96, 258-268 (1988).
7. S. Benes and W. H. McCormack, Inhibition of growth of Chlamvdia trachomatis by nonoxynol-9, Antimicrob. Agents Chemother., 27, 724-726 (1985).
8. H. Austin, W. C. Louv, and W. J. Alexander, A case control study of spermicides and gonorrhea, JAMA, 251, 2822-2824 (1984).
9. B. Singh, J. C. Cutler, and H. M. D. Utidjian, Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. II. Effect in vitro of vaginal contraceptives and non-contraceptive preparations on Treponema pallidum and Neisseria gonorrhoese, Br. J. Vener. Dis., 48, 57-64 (1972).
10. F. Rapp and H. Wrzos, Synergistic effect of human leukocyte interferon and nonoxynol-9 against herpes simplex virus type 2, Antimicrob. Agents Chemother., 28, 449-451 (1985).
11. A. E. Friedman-Kein, R. J. Klein, R. D. Glaser, and S. M. Czelusniak, Treatment of recurrent genital herpes with topical alpha interferon gel combined with nonoxynol-9, J. Am. Acad. Dermatol., 15, 989-994 (1986).
12. D. R. Hicks, L. S. Martin, J. P. Getchell, et al., Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes by nonoxynol-9 in vitro, Lancet, 1422-1423 (1985).
13. B. Voeller, Nonoxynol-9 and HTVL-III, Lancet, 1153 (1986).
14. M. Malkovsky, A. Newell, and A. G. Dalgleisch, Inactivation of HIV by nonoxynol-9, Lancet, 645 (1988).
15. G. A. Digenis and A. G. Digenis, High energy coprecipitate of nonoxynol oligomer, PVP and iodine having contraceptive and potent anti-HIV properties, US patent 5,380,523, 1995.
16. J. C. Kaplan, D. C. Crawford, A. G. Durno, and R. T. Schooley, Inactivation of human immunodeficiency virus by Betadine, Infect. Control, 8, 412-414 (1987).
17. M. A. Harbison and S. M. Hammer, Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine, J. Acquired Immune Defic. Syndr., 2, 16-20 (1989).
18. P. M. Zavos, J. R. Correa, R. Page, Y. Tanizawa, P. Fowler, and G. A. Digenis, unpublished data.
19. North American Science Association Inc. (NAMSA) reports of Triad HGC (report no. 95T 10593 00) and bilayer tablet (report no. 95T 12580 00), Northwood, OH.
20. G. A. Digenis and A. G. Digenis, Coated products with potent anti-HIV and antimicrobial properties, US patent 5,492,692, 1996.